Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 1 (4), 411-6

Megestrol Acetate in Cachexia and Anorexia


Megestrol Acetate in Cachexia and Anorexia

Shing-Shing Yeh et al. Int J Nanomedicine.


The aim is to review major clinical trials that have used megestrol acetate (MA) in the treatment of cachexia across several disease states. A review of general usage and potential side-effects are discussed. A theory that the newly approved nanocrystal formation of MA can better deliver this potent medication for treatment will also be reviewed.


Figure 1
Figure 1
Summary of proposed megestrol acetate (MA) mechanism for weight gain and potential side-effects. Abbreviations: CA, cancer; Con A, concanavalin A; HTN, hypertension; MA, megestrol acetate; Pha, phytohemagglutinin; PIC, pro-inflammatory cytokine; RX: treatment; S O WB, sense of well being; Sti, stimulation; WT, weight.

Similar articles

See all similar articles

Cited by 9 PubMed Central articles

See all "Cited by" articles


    1. Alakhov V, Pietrzynski G, Patel K, et al. Pluronic block copolymers and Pluronic poly(acrylic acid) microgels in oral delivery of megestrol acetate. J Pharm Pharmacol. 2004;56:1233–41. - PubMed
    1. Barak V, Schwartz A, Kalickman I, et al. Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines. Am J Med. 1998;104:40–7. - PubMed
    1. Bennett RG. 2003Megestrol complications Chest 123309– reply 310. - PubMed
    1. Berenstein E, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2005:CD004310. - PubMed
    1. Bojar H, Maar K, Staib W. The endocrine background of human renal cell carcinoma. IV. Glucocorticoid receptors as possible mediators of progestogen action. Urol Int. 1979;34:330–8. - PubMed

MeSH terms

LinkOut - more resources